Financial Report: Johnson & Johnson

2Q Revenues: $18.8 billion (+2%)
2Q Earnings: $3.8 billion (-4%)
YTD Revenues: $36.6 billion (+2%)
YTD Earnings: $8.2 billion (-2%)

Comments: Worldwide Pharmaceutical sales were flat at $8.6 billion in the quarter. Domestic sales were down 3%; international sales increased 3%, which reflected an operational increase of 6% and a negative currency impact of 3%. Remicade sales were down 14% to $1.5 billion. Zytiga sales were down 7% to $558 million. INVOKANA sales were down 23% to $295 million. DARZALEX sales were $299 million, up from $108 million in 2Q16. IMBRUVICA sales were $450 million, up 53%. Additional contributors to operational sales growth included STELARA, up 22% to $983 million and INVEGA SUSTENNA/XEPLION/TRINZA, up 12% to $629 million. During the quarter, the company completed the acquisition of Actelion Ltd., a biopharmaceutical company, for approximately $30 billion in cash.